The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
(Adds chairman interview, updates shares)
COPENHAGEN, May 10 (Reuters) - Lars Marcher, CEO of Danish medical device maker Ambu, who has presided over a roughly 5,000 percent rise in the company's shares since 2008, is to step down and be replaced by a former Johnson & Johnson executive.
Marcher had led the company's successful expansion of diagnostic and life-support devices for hospitals for more than 10 years, focusing on products such as single-use endoscopes.
Ambu's shares fell more than 10 percent on news of the management change.
Ambu said Marcher's replacement Juan-José Gonzalez would take on his new job from May 15.
"With Juan-José Gonzalez as CEO, we ensure that Ambu also has the necessary global experience to execute the announced strategy and ensure the successful commercialisation of our product launches," Chairman Jens Bager said in a statement on Friday.
Bager told Reuters Gonzales had "deep knowledge" of the U.S. medtech industry which was an important skill at a time where Ambu was aiming to expand globally with its new product ranges.
"The board has employed a new strong international profile and as a consequence Lars Marcher has left his position," Bager said, adding that the new employment contract had been signed early Friday morning.
He declined to comment further on the process.
Ambu's shares have risen about 4,750 percent since Marcher took the helm in 2008. They were down 12 percent by 0805 GMT on Friday set for their worst day since November 2018, Refinitiv data showed.
"From a financial perspective with regards to the result, it is difficult to find fault with Marcher's performance," Nordnet analyst Per Hansen said.
Bager said he would like to thank Marcher for his contribution to Ambu's growth over the past 10 years.
"We can only recognize that as very impressive, but now we are facing a new and very exiting development in the company's history," the chairman said.
Ambu said there would be one-off costs of 38 million Danish crowns ($5.7 million) relating to Marcher's departure -- covering his salary for a notice period and share options. It said its financial expectations for 2018-19 were unchanged, while Bager said that the company's current strategy was also unchanged.
Gonzalez, who is 46, is an American citizen and will move from the United States to Denmark to take up the role, Ambu said.
Gonzalez was at Johnson & Johnson until February this year, according to his LinkedIn profile. He was president the group's U.S. subsidiary DePuy Synthes, which makes orthopedic and neurosurgical products.
($1 = 6.6491 Danish crowns) (Reporting by Stine Jacobsen, additional reporting by Tommy Lund in Gdynia Editing by Keith Weir and Jane Merriman)